TM Pharma today announced positive results from its clinical Phase I/II study with its lead compound TM30338, a dual Y2-Y4 receptor agonist developed for the treatment of obesity and related diseases. Both the primary and secondary objective of the study were met. Thus, the study demonstrated that the drug candidate is safe and well tolerated in man. Importantly, in obese human subjects once-a-day subcutaneous (s.c.) dosing of TM30338 inhibited food intake at a statistically significant level up to at least 9 hours after dosing.
